Published in

American Association for the Advancement of Science, Science Advances, 2(8), 2022

DOI: 10.1126/sciadv.abj5666

Links

Tools

Export citation

Search in Google Scholar

Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission

Journal article published in 2022 by Ashish Goyal ORCID, Matthew Gardner ORCID, Bryan T. Mayer, Keith R. Jerome ORCID, Michael Farzan ORCID, Joshua T. Schiffer ORCID, E. Fabian Cardozo-Ojeda ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

eCD4Ig has an in vivo IC 50 of 25 μg/ml, and it may induce ART-free virus control if produced continually at 10 5 μg/day or more.